| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt does not have a specific protein target but functions as a structural lipid in biological membranes and liposomal formulations. As a phosphatidylglycerol, it is an anionic phospholipid that contributes negative charge to membranes. This negative charge allows the lipid to interact electrostatically with positively charged peptides and proteins. The asymmetric fatty acid composition (palmitic acid at sn-1, oleic acid at sn-2) affects membrane fluidity, curvature, and phase behavior. In liposomal drug delivery, the compound is used as a component to modulate liposome surface charge, stability, and interactions with biological membranes. Its role as a membrane component makes it a fundamental tool for biophysical and pharmaceutical studies.
|
|---|---|
| ln Vitro |
In vitro, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt is used in model membrane systems to study lipid-protein interactions and membrane properties. Its negative charge allows it to interact with positively charged peptides and proteins, making it useful for studying electrostatic interactions at membrane surfaces. The compound is used in liposome preparation for drug delivery studies, where it contributes to liposome stability, drug encapsulation, and surface charge modulation. In biophysical assays, the compound is used to measure membrane fluidity, lipid packing, and phase behavior using techniques such as fluorescence anisotropy, differential scanning calorimetry, and Langmuir-Blodgett trough experiments. Its asymmetric fatty acid composition makes it valuable for studying the effects of lipid asymmetry on membrane function.
|
| ln Vivo |
In vivo, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt is used as a component of liposomal drug delivery systems for preclinical studies. Liposomes containing this lipid are administered to rodents to evaluate the pharmacokinetics, biodistribution, and efficacy of encapsulated drugs. The negative charge of the lipid contributes to liposome stability and circulation time. Liposomes formulated with this lipid are typically taken up by the reticuloendothelial system, primarily in the liver and spleen. The lipid itself is metabolized by phospholipases to release fatty acids and lysophosphatidylglycerol, which enter fatty acid and phospholipid metabolic pathways. The compound's in vivo behavior is formulation-dependent, and its role is primarily as a structural component for drug delivery rather than as a therapeutic agent.
|
| Enzyme Assay |
The in vitro liposome preparation and characterization assays for this lipid typically involve dissolving the lipid (often in combination with other lipids such as phosphatidylcholine and cholesterol) in organic solvent, evaporating the solvent to form a lipid film, and hydrating the film with aqueous buffer. The resulting liposomes are extruded through polycarbonate membranes to achieve uniform size. Liposome size is measured by dynamic light scattering (DLS), and zeta potential is measured by electrophoretic light scattering to confirm the negative charge of the liposomes. Encapsulation efficiency is determined by separating free drug from liposome-encapsulated drug using size exclusion chromatography or ultracentrifugation, followed by drug quantification by HPLC or UV-Vis spectroscopy. Drug release kinetics are assessed by dialysis or by measuring drug concentration in the release medium over time. Liposome stability in serum is evaluated by monitoring size and drug leakage.
|
| Cell Assay |
For in vitro cellular assays, liposomes containing 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt are incubated with cultured cells (e.g., cancer cell lines, macrophages) at varying lipid concentrations. Cellular uptake is assessed using fluorescently labeled lipids or encapsulated fluorescent markers by flow cytometry or confocal microscopy. Cytotoxicity of empty liposomes and drug-loaded liposomes is evaluated using MTT or CellTiter-Glo assays. For drug delivery studies, the efficacy of encapsulated chemotherapeutic agents is compared to free drug controls. The compound's effects on cellular membrane properties and lipid raft organization are studied using fluorescent probes and imaging techniques. The negative charge of the lipid may enhance interactions with positively charged cell surface proteins. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, liposomes containing 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt are typically administered to rodents via intravenous injection. The liposomes may be used to deliver chemotherapeutic agents, nucleic acids, or imaging agents. Pharmacokinetic studies involve collecting blood samples at various time points and measuring drug or lipid concentrations by HPLC or LC-MS/MS. Biodistribution studies involve harvesting organs (liver, spleen, kidney, lung, tumor) and measuring drug or lipid content. In tumor models, the antitumor efficacy of drug-loaded liposomes is assessed by measuring tumor growth inhibition and survival. The stability of liposomes in circulation is evaluated by measuring the leakage of encapsulated markers. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of this lipid as a component of liposomal formulations are typically characterized in the context of the formulation. When administered as liposomes, the lipid components are taken up by the reticuloendothelial system, primarily in the liver and spleen. The compound is metabolized by phospholipases to release palmitic acid, oleic acid, and lysophosphatidylglycerol, which enter fatty acid and phospholipid metabolic pathways. The half-life of liposomal lipids in circulation ranges from hours to days, depending on the formulation, particle size, and surface modifications. The compound's distribution and elimination are influenced by its lipophilic nature and its incorporation into lipid bilayers. Detailed PK data for this specific lipid are limited, as it is primarily used as a formulation component.
|
| Toxicity/Toxicokinetics |
The toxicology of 1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt is primarily evaluated in the context of liposomal formulations. As a naturally occurring phospholipid, it is generally considered biocompatible and has low toxicity. In acute toxicity studies of liposomal formulations, the compound is well-tolerated at doses used for drug delivery. At high doses, liposomal lipids may cause mild inflammatory responses or RES saturation, but these effects are typically reversible. The compound itself is not genotoxic or carcinogenic. In repeated-dose studies, liposomal formulations containing this phospholipid show no significant organ toxicity or hematological abnormalities at therapeutic doses. The safety profile is consistent with other phospholipids used in FDA-approved liposomal drug products. The compound is for research use only.
|
| References | |
| Additional Infomation |
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium salt is a negatively charged phospholipid that interacts with positively charged peptides. It is used in lipid research, membrane biophysics, and liposome formulation for drug delivery. The compound has a molecular formula of C40H76NaO10P and a molecular weight of 770.99. It is not approved for human use and is available as a research-grade reagent for laboratory use only. Its negative charge and asymmetric fatty acid composition make it a valuable tool for studying lipid-protein interactions, membrane properties, and developing lipid-based drug delivery systems.
|
| Molecular Formula |
C40H76NAO10P
|
|---|---|
| Molecular Weight |
770.9890
|
| Exact Mass |
770.507
|
| CAS # |
268550-95-4
|
| Related CAS # |
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol;185435-28-3
|
| PubChem CID |
46891828
|
| Appearance |
White to off-white solid powder
|
| LogP |
10.885
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
52
|
| Complexity |
875
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC(CO)O)OC(=O)CCCCCCC/C=C\CCCCCCCC.[Na+]
|
| InChi Key |
FJXDNGDRHUDFST-XQYKCTAGSA-M
|
| InChi Code |
InChI=1S/C40H77O10P.Na/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-40(44)50-38(36-49-51(45,46)48-34-37(42)33-41)35-47-39(43)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2;/h17-18,37-38,41-42H,3-16,19-36H2,1-2H3,(H,45,46);/q;+1/p-1/b18-17-;/t37?,38-;/m1./s1
|
| Chemical Name |
sodium;2,3-dihydroxypropyl [(2R)-3-hexadecanoyloxy-2-[(Z)-octadec-9-enoyl]oxypropyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~32.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (1.62 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2970 mL | 6.4852 mL | 12.9703 mL | |
| 5 mM | 0.2594 mL | 1.2970 mL | 2.5941 mL | |
| 10 mM | 0.1297 mL | 0.6485 mL | 1.2970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
